Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Some other nutritional supplements, such as β-hydroxy β-methylbutyrate, creatine and vitamin D have been suggested to have an effect on muscle function.

Source: Nutrition. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Sarcopenia in daily practice: assessment and management

Study design awaiting verification · BMC Geriatrics · 2016

Original publication title

Sarcopenia in daily practice: assessment and management

Charlotte Beaudart; Eugène McCloskey; Olivier Bruyère; Matteo Cesari; Yves Rolland; René Rizzoli; Islène Araujo de Carvalho; Jotheeswaran Amuthavalli Thiyagarajan; Ivan Bautmans; Marie-Claude Bertière; Maria Luisa Brandi; Nasser M. Al-Daghri; Nansa Burlet; Etienne Cavalier; Francesca Cerreta; Antonio Cherubini; Roger Fielding; Evelien Gielen; Francesco Landi; Jean Petermans; Jean-Yves Reginster; Marjolein Visser; John Kanis; Cyrus Cooper

© The Author(s). 2016

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to be accurate and reliable in investigational settings, many are not easily applied to daily practice.

Source: Background

Abstract: What methods does the paper describe?

This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were afterwards organized for the whole group to make amendments and discuss further recommendations.

Source: Methods

Abstract: Results

This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire, the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered and involve the combination of both resistance and endurance based activity programmes with or without dietary interventions.

Development of a number of pharmacological interventions is also in progress.

Source: Results

Abstract: Conclusions

Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future.

Source: Conclusions
Authors’ abstract

Background

Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to be accurate and reliable in investigational settings, many are not easily applied to daily practice.

Methods

This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were afterwards organized for the whole group to make amendments and discuss further recommendations.

Results

This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire, the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered and involve the combination of both resistance and endurance based activity programmes with or without dietary interventions.

Development of a number of pharmacological interventions is also in progress.

Conclusions

Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future.

Publication and source details

Original title: Sarcopenia in daily practice: assessment and management

Charlotte Beaudart; Eugène McCloskey; Olivier Bruyère; Matteo Cesari; Yves Rolland; René Rizzoli; Islène Araujo de Carvalho; Jotheeswaran Amuthavalli Thiyagarajan; Ivan Bautmans; Marie-Claude Bertière; Maria Luisa Brandi; Nasser M. Al-Daghri; Nansa Burlet; Etienne Cavalier; Francesca Cerreta; Antonio Cherubini; Roger Fielding; Evelien Gielen; Francesco Landi; Jean Petermans; Jean-Yves Reginster; Marjolein Visser; John Kanis; Cyrus Cooper

BMC Geriatrics · 2016

© The Author(s). 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:57:44.574688+00:00

DOI: 10.1186/s12877-016-0349-4 · PMC5052976